ECM
ACOR

Endurant Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Endurant Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-80
Closed -$320K – 97
2015
Q2 		$320K Buy
80
+2
+3% +$7.73K 0.09% 92
2015
Q1 		$313K Buy
+78
New +$357K 0.1% 90

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Endurant Capital Management's ACOR Position: Q3 2015 in Review

Endurant Capital Management sold out of Acorda Therapeutics (ACOR) in Q3 2015, closing a stake of 80 shares — an estimated $320K sold.

Endurant Capital Management first reported a position in ACOR in Q1 2015 and held it in 2 quarters. The position peaked at $320K in Q2 2015. 176 funds tracked by Wall St. Rank hold ACOR as of Q3 2015.

  • Endurant Capital Management reported no remaining Acorda Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Endurant Capital Management sold 80 Acorda Therapeutics shares in Q3 2015, an estimated $320K.
  • Endurant Capital Management first reported a position in Acorda Therapeutics in Q1 2015 and held it in 2 quarters.
  • Endurant Capital Management's Acorda Therapeutics position peaked at $320K in Q2 2015.
  • 176 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2015.

Based on Endurant Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.